Drug Profile
Research programme: cannabinoid receptor CB1 antagonists - Bristol-Myers Squibb
Alternative Names: BMS-812204Latest Information Update: 11 Nov 2013
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Pyridazines; Small molecules; Triazoles
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 07 Nov 2013 Discontinued - Preclinical for Obesity in USA (PO)
- 01 Sep 2011 Preclinical development is ongoing in USA
- 20 Aug 2009 Pharmacodynamics, pharmacokinetics and adverse events data from Preclinical trials in Obesity presented at the 238th American Chemical Society National Meeting (238th-ACS-2009) ,